News | Stroke | February 16, 2023

Percent Insular Ribbon Infarction for Growth Rate Prediction, Outcomes in Large-Vessel Occlusive Stroke

Acute ischemic stroke patients with each PIRI score on 5-point scale

February 16, 2023 — According to an accepted manuscript published in ARRS’ American Journal of Roentgenology (AJR), percent insular ribbon infarction (PIRI) complements current stroke outcome predictors, classifying patients with slowly progressive stroke who could benefit from late-window endovascular thrombectomy (EVT).

Noting that PIRI was independently associated with infarct growth rate and 90-day outcome, “PIRI may help identify patients who could benefit from late-window EVT when requiring transfer to EVT-capable centers,” wrote head researcher Robert W. Regenhardt, MD, PhD, from the department of neurology at Massachusetts General Hospital and Harvard Medical School.

Analyzing a previous clinical trial of acute stroke patients untreated with reperfusion therapies from January 2007 to June 2009, Regenhardt et al. reevaluated 31 trial patients (median age, 71 years; 12 female, 19 male) with anterior-circulation large-vessel occlusion who underwent serial MRI examinations. Two neuroradiologists independently scored PIRI on presentation MRI—mild (0-1), moderate (2), severe (3-4)—based upon length ratios of the insula portion showing restricted diffusion to the insula’s total length. A 90-day modified Rankin Scale (mRS) was also obtained.

Ultimately, in multivariable models controlling for age, large-vessel occlusion location, and collateral pattern, PIRI category was a significant independent predictor of presentation-to-48-hour infarct growth rate (β=1.3) and 90-day mRS ≤2 (OR=0.2). Sensitivity and specificity for predicting 90-day mRS ≤2 were 90% and 84% for mild-to-moderate PIRI, versus 70% and 74% for symmetric collateral pattern.

“To our knowledge,” the authors of this AJR accepted manuscript added, “the present study is the first to show the PIRI category to be an independent predictor of 90-day mRS <2 in multivariable models.”

For more information: www.arrs.org


Related Content

Feature | Heart Failure | Kyle Hardner

Editor's Note: This is Part Three of a three-part series highlighting several of the presentations from the American ...

Home May 13, 2026
Home
News | Heart Failure

May 10, 2026 — Results from the first randomized trial evaluating microRNA inhibition in heart failure were presented ...

Home May 11, 2026
Home
Feature | Heart Failure | Kyle Hardner

Could a link between the heart, brain and immune system help reduce the occurrence of heart attacks and lessen the ...

Home May 04, 2026
Home
News | Heart Failure

April 21, 2026 — Nuwellis, Inc. has announced a software update to its Aquadex SmartFlow ultrafiltration platform. The ...

Home April 23, 2026
Home
News | Heart Failure

March 28, 2026 — Amgen announced today that Repatha (evolocumab), when added to statins or other low-density lipoprotein ...

Home April 06, 2026
Home
News | Heart Failure

March 24, 2026 — New research shows that small improvements to sleep, diet quality and physical activity, made in ...

Home March 25, 2026
Home
News | Heart Failure

March 16, 2026 — Cytokinetics has announced four presentations related to Myqorzo (aficamten) at the American College of ...

Home March 16, 2026
Home
Feature | Heart Failure | Rohit Sood, MD, PhD

Cardiovascular disease (CVD) is a serious global health burden that encompasses a broad group of diseases that affect ...

Home February 12, 2026
Home
News | Heart Failure

Feb. 3, 2026 — Bristol Myers Squibb has launched "Change the Target. Change What’s Possible," an educational campaign ...

Home February 03, 2026
Home
News | Heart Failure

Jan. 27, 2026 — A new national study reveals a stark disconnect between Americans’ desire for preventive cardiac ...

Home January 27, 2026
Home
Subscribe Now